Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02341534
Other study ID # HS058
Secondary ID Preserved Ejecti
Status Completed
Phase N/A
First received
Last updated
Start date August 7, 2015
Est. completion date November 3, 2021

Study information

Verified date November 2022
Source Biotronik SE & Co. KG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The BIO|GUARD-MI study investigates whether continuous arrhythmia monitoring and the consequent treatment after detected arrhythmias in patients after myocardial infarction with preserved cardiac function, but other risk factors, decreases the risk of major adverse cardiac events.


Description:

Patients randomized to the BioMonitor arm will receive an implantable cardiac monitor (ICM; BioMonitor) with remote monitoring function (Home Monitoring®). If the device detects and reports an arrhythmia, patients will be appropriately examined and treated. Patients randomized to the control arm will receive best proven treatment, but no implantable cardiac monitor.


Recruitment information / eligibility

Status Completed
Enrollment 802
Est. completion date November 3, 2021
Est. primary completion date November 3, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Patient has a history of MI according to guidelines - CHA2DS2-VASc-Score = 4 in men / = 5 in women - LVEF > 35 % as estimated within 6 months before enrollment but after conclusion of AMI treatment - Patient accepts activation of Home Monitoring® - Patient is able to understand the nature of the clinical study and has provided written informed consent Exclusion Criteria: - Patients with hemorrhagic diathesis - Permanent oral anticoagulation treatment for atrial fibrillation - Indication for chronic renal dialysis - Pacemaker or ICD implanted or indication for implantation - Parkinson's disease - Life expectancy < 1 year - Participation in another interventional clinical Investigation - Age < 18 years - Woman who are pregnant or breast feeding

Study Design


Intervention

Device:
BioMonitor
Patients will be implanted with the BioMonitor + Home Monitoring feature

Locations

Country Name City State
Australia The Canberra Hospital Canberra
Australia Lyell McEwin Hospital (LMH) Elizabeth Vale South Australia
Australia East Metropolitan Health Service Trading AS Royal Perth HOSPITAL Perth Western Australia
Austria Kepler Universitätsklinikum Linz Oberösterreich
Belgium OLV Ziekenhuis Aalst Aalst
Belgium Ziekenhuis Oost Limburg Genk (ZOL Genk) Genk
Czechia Nemocnice Ceské Budejovice Ceské Budejovice
Czechia Fakultní nemocnice Olomouc Olomouc
Czechia Institute for Clinical and Experimental Medicine (IKEM) Praha
Denmark Aalborg Universitetshospitel Aalborg
Denmark Århus Universitetshospital Århus N
Denmark Rigshospitalet Copenhagen
Denmark Regionshospitalet Herning Herning
Denmark Odense University Hospital (OUH) Odense Syddanmark
Denmark Sjaellands Universitets Hospital, Roskilde Roskilde
Denmark Regionshospitalet Viborg Viborg
France CHRU de Tours - Hôpital Trousseau Chambray-lès-Tours
France Hôpital Gabriel Montpied, Clermont Ferrand Clermont-Ferrand
Germany Zentralklinik Bad Berka GmbH Bad Berka
Germany Herz- und Gefäß- Klinik GmbH Bad Neustadt Bad Neustadt a.d. Saale
Germany Charité Universitätsklinikum - Campus Benjamin Franklin Berlin
Germany Vivantes Humboldt-Klinikum Berlin
Germany Vivantes-Krankenhaus Spandau Berlin
Germany Städtisches Krankenhaus Bielefeld-Mitte Bielefeld
Germany Klinikum Coburg Coburg
Germany Klinikum Fürth Fürth
Germany SRH Wald-Klinikum Gera GmbH Gera
Germany Ernst-Moritz-Arndt-Universität Greifswald Greifswald
Germany Klinikum der Universität Jena Jena
Germany Herzzentrum Leipzig GmbH Leipzig
Germany Universitätsklinikum Schleswig-Holstein (UKSH) - Campus Lübeck Lübeck
Germany Johannes Wesling Klinikum Minden Minden
Germany Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH Villingen-Schwenningen
Germany Universitätsklinikum Würzburg Würzburg
Hungary National Hospital of Cardiology Balatonfüred
Hungary Gottsegen György Budapest
Hungary Hungarian Defence Forces Military Hospital Budapest
Hungary Semmelweis Medical University Budapest
Hungary The Debrecen University of Medicine Debrecen
Hungary The University of Pécs Pécs
Latvia Pauls Stradins Clinical University Hospital Riga
Latvia Riga East Clinical University Hospital Riga
Netherlands Onze Lieve Vrouwe Gasthuis Amsterdam (OLVG) Amsterdam
Netherlands Scheperziekenhuis, Treant Zorggroep Emmen
Poland Klinika i Katedra Chorób Wewn. i Kardiologii Warszawa
Poland National Institute of Cardiology Warszawa
Slovakia SÚSCCH Banska Bystrica
Slovakia East-Slovak Cardiology Institute (VUSCH) Košice
Spain Hospital del Mar Barcelona
Spain Hospital de la Princesa Madrid
Spain Hospital Universitario Ramón y Cajal Madrid
United States Abington Medical Specialists Abington Pennsylvania
United States Altru Health System Grand Forks North Dakota
United States Metro Knoxville HMA LLC Knoxville Tennessee
United States Carolina Heart Specialists Lancaster South Carolina
United States University of Rochester Medical Center Rochester New York
United States Carolina Cardiology Associates Rock Hill South Carolina
United States Gateway Cardiology Saint Louis Missouri
United States St. Louis Heart and Vascular Saint Louis Missouri

Sponsors (3)

Lead Sponsor Collaborator
Biotronik SE & Co. KG IHF GmbH - Institut für Herzinfarktforschung, Qmed Consulting A/S

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Belgium,  Czechia,  Denmark,  France,  Germany,  Hungary,  Latvia,  Netherlands,  Poland,  Slovakia,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Mean Value of EQ-5D-5L The EQ-5D-5L questionnaire was administered during the telephone contacts to estimate utility values at different time points for an economic evaluation.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The scale reaches from 0 (worst status) to 100 (best possible status).
From Baseline measurement to 60 months. All data are collected for the period from randomization until official study end or drop-out, for all enrolled patients.
Primary Kaplan-Meier Estimate of Percentage of Participants With Major Adverse Cardiac Event (MACE) The primary endpoint is defined as death for cardiovascular reasons or unplanned hospitalization for cardiovascular reasons as per study protocol.
The time period with regards to the Time-to-Event Outcome Measures starts with the randomization of the patient.
All patients will be assessed for Time-to-Event Outcome Measures until formal study termination is announced or until the individual patient meets a drop out criterion in accordance with the study protocol. The study period is estimated 6 years.
2 years
Secondary Kaplan-Meier Estimate of Percentage of Participants With Outcome of Death Due to Any Cause The occurrence of death due to any cause will be recorded and analyzed. 2 years
Secondary Kaplan-Meier Estimate of Percentage of Participants With Outcome of Death Due to Any Cause or Heart Transplantation Assessment of the time from randomization to death for any reason or heart transplantation during the clinical investigation. 2 years
Secondary Kaplan-Meier Estimate of Percentage of Participants With Outcome of Cardiovascular Death or Heart Transplantation Assessment of the time from randomization to cardiovascular death or heart transplantation during the clinical investigation. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. 2 years
Secondary Kaplan-Meier Estimate of Percentage of Participants With Worsening of Heart Failure Requiring Hospitalization or Urgent Visit Assessment of the time from randomization to first hospitalization or urgent visit for worsening of the patient status due to heart failure, or death due to heart failure. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. 2 years
Secondary Kaplan-Meier Estimate of Percentage of Participants With an Arrhythmia Resulting in Hospitalization Assessment of the time from randomization to the first hospitalization resulting from an arrhythmia or death resulting from arrhythmia. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. 2 years
Secondary Kaplan-Meier Estimate of Percentage of Participants With Acute Coronary Syndrome Resulting in Hospitalization Assessment of the time from randomization to the first hospitalization resulting from acute coronary syndrome or death resulting from acute coronary syndrome. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. 2 years
Secondary Kaplan-Meier Estimate of Percentage of Participants With Stroke Resulting in Hospitalization Assessment of the time from randomization to the first hospitalization resulting from stroke or death resulting from stroke. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. 2 years
Secondary Kaplan-Meier Estimate of Percentage of Participants With Major Bleeding Resulting in Hospitalization Assessment of the time from randomization to the first hospitalization resulting from major bleeding or death resulting from major bleeding. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. 2 years
Secondary Kaplan-Meier Estimate of Percentage of Participants With Systemic Embolism Resulting in Hospitalization Assessment of the time from randomization to the first hospitalization resulting from systemic embolism or death resulting from systemic embolism. A specified endpoint definition will be given by the members of the EAEC and documented in the charter agreement. 2 years
Secondary Kaplan-Meier Estimate of Percentage of Participants With an Arrhythmia Assessment of the time from randomization to first arrhythmia. 2 years
Secondary Type of Initiated Therapies Post-hoc categorical summary of most frequent therapies initiated after detection of arrhythmias. All data are collected for the period from randomization until official study end or drop-out, for all enrolled patients, up to 6 years.
Secondary Kaplan-Meier Estimate of Percentage of Participants Receiving Therapy After Arrhythmia Diagnosis Assessment of the time from randomization to first therapy. In this context therapy is the attempted remediation of the patient's regular heartbeat. 2 years
Secondary Change in World Health Organization Five Well-being Index (WHO-5) From 6 Months to 24 Months. A further secondary endpoint is the assessment of the patient's well-being. The patient's well-being will be recorded during the regular telephone contacts using the WHO-5 Well-being Index. The scale reaches from 0 (worst status) to 100 (best possible status). We report the intraindividual change from 6-months to 24-months. All data are collected for the period from randomization until official study end or drop-out, for all enrolled patients.
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Completed NCT04507529 - Peer-mentor Support for Older Vulnerable Myocardial Infarction Patients N/A
Recruiting NCT06066970 - Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery
Recruiting NCT03620266 - Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI N/A
Completed NCT04097912 - Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT03668587 - Feasibility and Security of a Rapid Rule-out and rule-in Troponin Protocol in the Management of NSTEMI in an Emergency Departement
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Recruiting NCT05371470 - Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation N/A
Recruiting NCT04562272 - Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT06007950 - Time-restricted Eating Study (TRES): Impacts on Anthropometric, Cardiometabolic and Cardiovascular Health N/A
Withdrawn NCT05327855 - Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) Phase 2
Recruiting NCT02876952 - High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients N/A
Completed NCT02917213 - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed NCT02711631 - Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation N/A
Completed NCT02552407 - Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis N/A
Completed NCT02382731 - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction N/A